Neuromuscular junction disease

Medical Marijuana Cannabidiol Pipeline Insight Report 2021: Focus on 25 Companies & 50 Pipeline Drugs - ResearchAndMarkets.com

Retrieved on: 
星期一, 十月 18, 2021
Tobacco, Retail, Alternative Medicine, Health, Olive oil, EB, Diabetes, CB2, Pharma, Endothelium, Obstructive sleep apnea, TS, Agitation, Dermatomyositis, PEA, Cancer, Depression, Cannabinoid, INMED, Pain, Red, Spasticity, Epidermolysis bullosa, Systemic scleroderma, Health, Cystic fibrosis, Medical cannabis, THC, Therapy, Nausea, Multiple sclerosis, Disease, Neuromuscular junction disease, Fibroblast, Inflammation, Patient, Tourette syndrome, Dementia, Appetite, Chronic pain, Cannabinol, Arthritis, Hidradenitis suppurativa, Swelling, Entourage effect, University College London, Mergers and acquisitions, Safety, Dronabinol, Anxiety, Research, Muscle, III, Kindler syndrome, Timeline of cannabis laws in the United States, OSA, UCL, Dietary supplement, Drug, Pharmaceutical industry

"Medical Marijuana - Cannabidiol - Pipeline Insight, 2021" report provides comprehensive insights for about 25+ companies and 50+ pipeline drugs in Medical Marijuana - Cannabidiol pipeline landscape.

Key Points: 
  • "Medical Marijuana - Cannabidiol - Pipeline Insight, 2021" report provides comprehensive insights for about 25+ companies and 50+ pipeline drugs in Medical Marijuana - Cannabidiol pipeline landscape.
  • Currently, the two main cannabinoids from the marijuana plant that are of medical interest are THC and CBD.
  • How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Medical Marijuana - Cannabidiol?
  • What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Medical Marijuana - Cannabidiol therapeutics?

Survey Shows Impact of Myasthenia Gravis Specialists on Treatment Perspectives, Condition Knowledge

Retrieved on: 
星期三, 六月 2, 2021
Branches of biology, Organ systems, Autoimmune diseases, Anatomy, Myasthenia gravis, Myasthenia, Weakness, Neuromuscular junction, Thymectomy, Neuromuscular junction disease

The inaugural Myasthenia Gravis In America survey illuminates the perspectives and experiences of people living with myasthenia gravis.

Key Points: 
  • The inaugural Myasthenia Gravis In America survey illuminates the perspectives and experiences of people living with myasthenia gravis.
  • Myasthenia gravis (MG) is a rare neuromuscular condition in which antibodies destroy the communication between nerves and muscles; in its most common form, MG leads to fluctuating weakness among the voluntary muscles.
  • According to the Myasthenia Gravis Foundation of America, there are as many as 60,000 people living with the condition.
  • The Myasthenia Gravis In America survey, which fielded from Oct. 14, 2020 to Feb. 11, 2021, included responses from 600 people living with myasthenia gravis.

Global Myasthenia Gravis Epidemiology and Patient Flow Report 2020-2035 - ResearchAndMarkets.com

Retrieved on: 
星期三, 五月 5, 2021
Health, General Health, Autoimmune diseases, Myasthenia gravis, Myasthenia, Neuromuscular junction disease, Myaware

b'The "Global Myasthenia Gravis Epidemiology and Patient Flow - 2021" report has been added to ResearchAndMarkets.com\'s offering.\nGlobal Myasthenia Gravis Epidemiology and Patient Flow Analysis - 2021, provides Myasthenia Gravis epidemiology, demographics, and patient flow.

Key Points: 
  • b'The "Global Myasthenia Gravis Epidemiology and Patient Flow - 2021" report has been added to ResearchAndMarkets.com\'s offering.\nGlobal Myasthenia Gravis Epidemiology and Patient Flow Analysis - 2021, provides Myasthenia Gravis epidemiology, demographics, and patient flow.
  • The data is presented by Pharma G7 countries including the US, France, Spain, Italy, UK, Japan.\nThe research provides population data to characterize Myasthenia Gravis patients, history of the disease at the population level (Myasthenia Gravis prevalence, Myasthenia Gravis incidence) and at the clinical level (from diagnosis to treated patients).
  • It also helps to identify patient sub-groups (age, gender, sub-groups) to understand targeted population for research and development, commercialization.\nDemographics: Myasthenia Gravis patients by age group, gender\nThe data from this research will help executives:\nEstablish basis for Myasthenia Gravis market sizing, assessing market potential, and developing drug forecast models\nIdentify Myasthenia Gravis patients segments through age groups, gender, and disease sub-types\nEvaluate Myasthenia Gravis market opportunities, identify target patient population\nView source version on businesswire.com: https://www.businesswire.com/news/home/20210505005483/en/\n'

Worldwide Myasthenia Gravis Industry to 2024 - Develop In-depth Knowledge of Competition and Markets - ResearchAndMarkets.com

Retrieved on: 
星期一, 九月 14, 2020
Health, Pharmaceutical, Autoimmune diseases, Myasthenia gravis, RTT, Myasthenia, Medical tests, Neuromuscular junction disease

This research report provides comprehensive insights into the Myasthenia Gravis pipeline, epidemiology, market valuations, drug sales, market forecast, drug forecasts, and market shares.

Key Points: 
  • This research report provides comprehensive insights into the Myasthenia Gravis pipeline, epidemiology, market valuations, drug sales, market forecast, drug forecasts, and market shares.
  • This research analyzes and forecasts the Myasthenia Gravis market size and drug sales.
  • This research covers the following: Myasthenia Gravis treatment options, Myasthenia Gravis late stage clinical trials pipeline, Myasthenia Gravis prevalence by countries, Myasthenia Gravis market size and forecast by countries, key market events and trends, drug sales and forecast by countries, and market shares by countries.
  • Myasthenia Gravis pipeline: Find out drugs in clinical trials for the treatment of Myasthenia Gravis by development phase 3, phase 2, and phase 1, by pharmacological class and company
    Myasthenia Gravis drugs: Identify key drugs marketed and prescribed for Myasthenia Gravis in the US, including trade name, molecule name, and company
    Myasthenia Gravis market valuations: Find out the market size for Myasthenia Gravis drugs in 2019 by countries.

Myasthenia Gravis Pipeline Review, H1 2020: Analysis by Stage of Development, Drug Target, Mechanism of Action, Route of Administration and Molecule Type

Retrieved on: 
星期五, 一月 24, 2020
RTT, Myasthenia, Immunology, Acetylcholinesterase inhibitors, Neuromuscular junction disease

DUBLIN, Jan. 24, 2020 /PRNewswire/ -- The "Myasthenia Gravis - Pipeline Review, H1 2020" drug pipelines has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • DUBLIN, Jan. 24, 2020 /PRNewswire/ -- The "Myasthenia Gravis - Pipeline Review, H1 2020" drug pipelines has been added to ResearchAndMarkets.com's offering.
  • The Pharmaceutical and Healthcare latest pipeline guide Myasthenia Gravis - Pipeline Review, H1 2020, provides comprehensive information on the therapeutics under development for Myasthenia Gravis (Immunology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type.
  • The Myasthenia Gravis (Immunology) pipeline guide also reviews of key players involved in therapeutic development for Myasthenia Gravis and features dormant and discontinued projects.
  • The pipeline guide evaluates Myasthenia Gravis (Immunology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

Global Myasthenia Gravis Treatment Market Size, Share & Trends Analysis Report 2019-2026 - ResearchAndMarkets.com

Retrieved on: 
星期四, 十二月 12, 2019
Health, Pharmaceutical, Organ systems, Nervous system, Autoimmune diseases, Myasthenia gravis, RTT, Myasthenia, Neuromuscular junction, Weakness, Neuromuscular junction disease

The "Myasthenia Gravis Treatment Market Size, Share & Trends Analysis Report by Treatment (Medication, Surgery), by End Use (Hospitals, Clinics), and Segment Forecasts, 2019 - 2026" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Myasthenia Gravis Treatment Market Size, Share & Trends Analysis Report by Treatment (Medication, Surgery), by End Use (Hospitals, Clinics), and Segment Forecasts, 2019 - 2026" report has been added to ResearchAndMarkets.com's offering.
  • Increasing awareness of rare diseases, emergence of biologics, and growing adoption of immunotherapies & immunosuppressant are driving the myasthenia gravis (MG) treatment market.
  • Myasthenia gravis (MG) is a rare autoimmune disorder caused by an antibody mediated neuromuscular transmission obstruction that results in skeletal muscle weakness.
  • Medication held the largest market share in the treatment segment and is expected to maintain its market leading position through the forecast period.

Global $2+ Billion Myasthenia Gravis Treatment Market Outlook, 2026 - High Adoption of Immunotherapies and Recent Approval of Promising Drugs Drives Medications

Retrieved on: 
星期四, 十二月 12, 2019
Autoimmune diseases, Myasthenia gravis, RTT, Myasthenia, Neuromuscular junction disease

The global myasthenia gravis treatment market size is expected to reach USD 2.06 billion by 2026 at a CAGR of 7.5% through the forecast period, according to this report.

Key Points: 
  • The global myasthenia gravis treatment market size is expected to reach USD 2.06 billion by 2026 at a CAGR of 7.5% through the forecast period, according to this report.
  • Increasing awareness of rare diseases, emergence of biologics, and growing adoption of immunotherapies & immunosuppressant's are driving the myasthenia gravis (MG) treatment market.
  • According to the National Organization for Rare Disorders (NORD), in the U.S. around 14-40 per 100,000 individuals suffer from myasthenia gravis.
  • This can be attributed to the high adoption of immunotherapies and the recent approval of promising drugs.

Global Generalized Myasthenia Gravis (gMG) Epidemiology Forecast to 2028 - ResearchAndMarkets.com

Retrieved on: 
星期四, 十一月 7, 2019
Health, General Health, Autoimmune diseases, GMG, Myasthenia gravis, Myasthenia, Neuromuscular junction disease

The "Generalized Myasthenia Gravis (gMG) - Epidemiology Forecast to 2028" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Generalized Myasthenia Gravis (gMG) - Epidemiology Forecast to 2028" report has been added to ResearchAndMarkets.com's offering.
  • The Generalized Myasthenia Gravis epidemiology division provides insights about historical and current patient pool and forecasted trend for every seven major countries.
  • The epidemiology data for Generalized Myasthenia Gravis are studied through all possible division to give a better understanding of the disease scenario in 7MM.
  • The report provides the segmentation of the disease epidemiology by auto-antibodies-specific cases of Generalized Myasthenia Gravis in 7MM.

Myasthenia Gravis - Pipeline Review, H1 2019: Analysis by Stage of Development, Drug Target, Mechanism of Action, Route of Administration and Molecule Type - ResearchAndMarkets.com

Retrieved on: 
星期二, 四月 16, 2019
Health, Pharmaceutical, Myasthenia gravis, RTT, Myasthenia, Immunology, Neuromuscular junction disease

Myasthenia Gravis - Pipeline Review, H1 2019 provides comprehensive information on the therapeutics under development for Myasthenia Gravis (Immunology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type.

Key Points: 
  • Myasthenia Gravis - Pipeline Review, H1 2019 provides comprehensive information on the therapeutics under development for Myasthenia Gravis (Immunology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type.
  • The Myasthenia Gravis (Immunology) pipeline guide also reviews of key players involved in therapeutic development for Myasthenia Gravis and features dormant and discontinued projects.
  • The pipeline guide reviews pipeline therapeutics for Myasthenia Gravis (Immunology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide evaluates Myasthenia Gravis (Immunology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

Global Myasthenia Gravis Market 2017-2018 & 2026: Increase in Occurrence of Autoimmune Disorders and Strong Pipeline Propelling Market Growth

Retrieved on: 
星期五, 一月 18, 2019
Autoimmune diseases, Anatomy, Medicine, Nervous system, Myasthenia gravis, RTT, Myasthenia, Neuromuscular disease, Weakness, Neuromuscular junction, Autoimmunity, Neuromuscular junction disease

The "Myasthenia Gravis - Global Market Outlook (2017-2026)" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Myasthenia Gravis - Global Market Outlook (2017-2026)" report has been added to ResearchAndMarkets.com's offering.
  • Increasing health care spending & improving health care infrastructure, increase in occurrence of autoimmune disorders and strong pipeline in its treatment are some of the key factors propelling the market growth.
  • However, limited availability of FDA approved drugs and costly treatment options are some issues restricting the market growth.
  • Myasthenia gravis is a chronic autoimmune neuromuscular disorder that is characterized by variable weakness of the voluntary muscle groups.